ETAA1_HUMAN ETAA1 ELISA tesk kit
- Known as:
- ETAA1_HUMAN ETAA1 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16434
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- ETAA1_HUMAN ETAA1 ELISA tesk kit
Related genes to: ETAA1_HUMAN ETAA1 ELISA tesk kit
- Gene:
- ETAA1 NIH gene
- Name:
- ETAA1 activator of ATR kinase
- Previous symbol:
- -
- Synonyms:
- ETAA16
- Chromosome:
- 2p14
- Locus Type:
- gene with protein product
- Date approved:
- 2006-08-14
- Date modifiied:
- 2019-01-25
Related products to: ETAA1_HUMAN ETAA1 ELISA tesk kit
Related articles to: ETAA1_HUMAN ETAA1 ELISA tesk kit
- Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting toxicity of cancer treatment, yet reliable biomarkers to predict individual susceptibility remain lacking. Germline genetic variation has been widely investigated as a potential contributor to CIPN risk; however, the consistency and clinical utility of these associations remain unclear. We performed a systematic review of genetic association studies evaluating CIPN across neurotoxic chemotherapies. PubMed, Embase, Web of Science, and the Cochrane Library were searched (April 2025) for human studies assessing germline variants in relation to clinician- or patient-reported CIPN. Eligible studies were identified in four major drug classes: vincristine, taxanes, platinum agents, and bortezomib. Study characteristics, phenotyping approaches, ancestry, and variant-level data were extracted, and study quality was assessed using Q-Genie. Meta-analysis was not performed due to substantial heterogeneity in study design and outcome measures. 72 studies were included, predominantly involving cohorts of European ancestry. The most consistently replicated loci were CEP72 and ETAA1 for vincristine-induced neuropathy; EPHA5, FGD4, and FZD3 for taxane-induced neuropathy; and ABC transporter genes and GSTP1 for platinum-induced neuropathy. For bortezomib, associations involving TRPV1, DNA repair pathways, and inflammatory signalling showed emerging but largely non-replicated evidence. Across studies, marked heterogeneity in CIPN definitions, phenotyping instruments, statistical approaches, and effect allele reporting limited comparability and reproducibility. Collectively, these findings indicate that current pharmacogenomic approaches to CIPN are constrained by poor replication, population bias, and inconsistent methodology, which hinder translation into clinically actionable biomarkers. Future progress will require harmonised phenotyping, multi-ancestry genome-wide studies, and integration of functional validation to enable robust risk stratification and precision oncology approaches to CIPN. - Source: PubMed
Publication date: 2026/07/09
Maganti AdityaRankothge IsharaSakadales HunterKok EthanBritton JamesRao NeilShatunova SvetlanaShimell KatherineZambrano Paula Manuela RojasPark Susanna BSchweitzer DanielLaakso E-LiisaYengo LoicVetter IrinaStarobova Hana - The ATR protein kinase preserves genomic integrity during DNA replication by controlling checkpoints needed for the orderly progression of S phase and for the responses to replication stress. ATR, with its obligate partner ATRIP, is activated by the TOPBP1 and ETAA1 proteins, which control different branches of ATR signaling. TOPBP1 is essential for induction of the S phase checkpoint in response to stalled replication forks, while ETAA1 is required for timely progression to mitosis from an unperturbed S phase. TOPBP1 and ETAA1 contain ATR-activating domains (AADs) of limited homology, but how they activate ATR has not yet been fully elucidated. Here we present the 3.0-Å cryo-EM structure of the human ATR-ATRIP complex bound to the TOPBP1 AAD, showing that TOPBP1 activates ATR by inducing a global conformational change that allosterically realigns active site residues in the kinase domain ~70 Å away. We also present the 3.3-Å structure of the ATR-ATRIP-ETAA1 AAD complex, which reveals a binding mode distinct from TOPBP1. Our data suggest that the distinct binding modes of TOPBP1 and ETAA1 contribute to the different cellular contexts and outcomes of ATR-ATRIP activation. - Source: PubMed
Publication date: 2026/07/23
Li BurenYaseen AyatPavletich Nikola P - BACKGROUND: Understanding the genetic basis of adaptation to extreme environments is crucial in evolutionary biology. Gannan Tibetan sheep, which thrive in high altitudes with thin air and cold climates, demonstrate remarkable resilience. However, the genetic basis of their adaptations remains poorly understood. In this study, we conducted whole-genome resequencing of three indigenous Tibetan sheep breeds, including Ganjia (n = 12), Oula (n = 12), Kecai (n = 12), from the Gannan Tibetan Autonomous Prefecture (average altitude of 3,500 m) in China. By integrating our data with previously published genomic data of sheep from northern China (Altitude below 1,500 m), we examined the genetic population structure, ancestry components, and signatures of positive selection. RESULTS: Our analyses, including principal component analysis, neighbor-joining tree construction, and ADMIXTURE, revealed that the three indigenous Tibetan sheep breeds share a common ancestry with other Tibetan sheep breeds, yet exhibit distinct population differentiation. Moreover, all three breeds display high genetic diversity, which enhances their adaptation to harsh local environments. Through selective sweep analysis, we identified genes associated with cold tolerance and high-altitude adaptation. These genes are involved in mitochondrial function and oxidative stress (LONP1, NDUFA11, NDUFB4 and HSD11B1L), cardiorespiratory and vascular function (FECH, TNFAIP3), and fat metabolism and thermogenesis (ACSL6, PDGFD, CES3, MTCH2, TMEM8B, SPAG8, ETAA1, ZIC1, ATG5, and HAO2). Additionally, we identified candidate regions containing genes related to immunity and physical traits. CONCLUSION: This study provides a comprehensive overview of the genomic variations, ancestry compositions, and selective signals linked to high-altitude traits in Gannan indigenous Tibetan sheep. Our findings offer valuable insights into the breeding and management of Tibetan sheep. - Source: PubMed
Publication date: 2026/03/27
Lv ChenxiaoChen LiliZou PanChen YanMa Yi - The severe, degenerative muscle condition known as Duchenne Muscular Dystrophy (DMD) typically manifests in early childhood. - Source: PubMed
Publication date: 2026/02/06
Rizk Sara KamalEzzat Eman MohamedAbuhegazy AyaEl-Ghlban Samah - Leukemia is the most common cancer in children, and 10%-15% of patients with leukemia/lymphoma carry pathogenic germline cancer-predisposing variants. Identifying these variants is critical for understanding the genetic predisposition and optimizing clinical management. - Source: PubMed
Publication date: 2025/09/09
Onder GizemOzdemir OzkanTaylan FulyaCanpolat CengizYalcin KorayErbey FatihSozmen Banu OflazAsarcikli FikretBayhan TuranAkcabelen Yunus MuratYarali NeseOzbek Namik YasarBozkaya Ikbal OkKacar DilekErgun BerkAkkus AlperAlbayrak DavutInce ElifDemirsoy UgurOzdemir Gul NihalDogru OmerAras SedaAydin EylulUnal BusraAmanvermez UfukDogan Ozlem AkgunAkyoney SezerSayitoglu MugeNordgren AnnBugra Agaoglu NihatOzbek UgurNg Ozden Hatirnaz